When it comes to looking for outsized returns among ASX shares, it pays to check in with the professionals.

I’ve reviewed the reports coming out of the major broking houses and zeroed in on four from Canaccord Genuity, which profile companies that could do very well indeed.

Let’s see which companies they like at the moment.

Bravura Solutions Ltd (ASX: BVS)

Shares in Bravura jumped last week after the company delivered a better-than-expected earnings update for the past financial year.

The company said revenue would be within its previously guided range of $280 to $285 million, but cash EBITDA would be about $77 million, compared with previous guidance of $69 to $73 million.

Managing Director Colin Greenhill said the company had “continued to manage costs well whilst investing in core technology and exploring new initiatives”.

Canaccord Genuity said in its note to clients they believed cost management was the key to the result.

They said:

With costs very tightly managed in the half, we believe this positions BVS well entering FY27. With the new financial year potentially having lower project work, in our view, given FY26 featured work on the Aware and Telstra Super merger (of which Aware has labelled as completed), the potential for lower FY27 project revenue seems to be well managed by the cost-base being tightly managed.

The broker has a $2.73 price target on Bravura shares compared to $2.17 at the time of writing.

Light & Wonder Inc (ASX: LNW)

Canaccord Genuity said a recent share price pullback has Light & Wonder shares trading near 12-month lows, “and offering valuation constructs not seen in recent years”.

They added:

In addition, a widening of the discount to Aristocrat Leisure (ASX: ALL) has been apparent in recent months at levels not far from historic peaks. We remain attracted to the LNW thesis and consider the business to have a solid medium-term growth profile.

The broker has a $182 price target on Light & Wonder shares compared to $102.78 at the time of writing.

Mesoblast Ltd (ASX: MSB)

This drug company recently reported its quarterly sales results for its flagship drug Ryoncil, notching up US$36 million for the quarter and US$115 million for the full year.

The company’s Chief Executive Officer, Dr Silviu Itescu, said Mesoblast was anticipating continued revenue growth in the current financial year, “in line with momentum we are seeing across major U.S. paediatric centres”.

Canaccord Genuity said it viewed consensus estimates of US$180 to US$190 million in Ryoncil sales this year as ambitious, but still has a bullish share price target of $3.23, up from $2.34 at the time of writing.

Pantoro Gold Ltd (ASX: PNR)

Canaccord Genuity has a very bullish $4.20 share price target on this company, compared to the price of $2.04 at the time of writing, but stresses that this is a speculative buy for investors.

Pantoro missed production estimates for the June quarter, but Canaccord said the longer-term story was of interest.

PNR expects to release its 5-year production plan this quarter alongside its annual Resource and Reserve update, which we expect will incorporate the new high-grade underground zones being delineated by PNR’s extensive ongoing growth program. We note PNR has reaffirmed its long-term growth target of up to 200kozpa of production.

This compares to the current guidance for FY27 of 90,000 to 105,000 ounces of gold.

The post 4 ASX shares which could improve by 25% to more than 100% appeared first on The Motley Fool Australia.

More reading

• Leading brokers name 3 ASX shares to buy today
• Here are the top 10 ASX 200 shares today
• Why Mesoblast shares could double in value
• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Bravura Solutions and Light & Wonder Inc. The Motley Fool Australia has recommended Light & Wonder Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are looking for big returns and have a high tolerance for risk, then read on.

That’s because listed below is one ASX share that Bell Potter believes could rocket higher over the next 12 months.

Which ASX All Ords share?

The share that has caught the eye of Bell Potter is Aroa Biosurgery Ltd (ASX: ARX).

It is a commercial stage medical device company that operates within the wound care and soft tissue reconstruction sector.

Bell Potter was pleased to see that the company has successfully completed a prospective randomised controlled trial for Symphony in diabetic foot ulcers.

It highlights that the “preliminary results [are] indicating the primary endpoint of complete wound closure at 12 weeks was met.”

This is good news because the Symphony product could have a billion-dollar market opportunity. It commented:

Although the full dataset remains due in Q3 FY27, the readout provides important clinical validation ahead of Symphony’s commercial launch and supports its positioning under a tougher coverage framework. That early validation arrives as the CY26 CMS reimbursement reset continues to disrupt the US skin substitute market. 

The new US$127.14/cm² flat rate has compressed the elevated pricing underpinning many legacy products, with Organogenesis and MiMedx both reporting wound-care revenue declines of at least 60% in Q1 CY26 and consensus expecting pressure to persist through the year. We estimate market size in outpatient care at greater than US$1b.

Time to buy

According to the note, the broker has retained its buy rating and $1.09 price target on the ASX All Ords share. Based on its current share price of 58.5 cents, this implies potential upside of 86% for investors over the next 12 months.

Touching on its outlook and investment thesis, Bell Potter said:

Beyond the clinical readouts, 2H CY26 should bring further clarity on the reimbursement environment. Key watchpoints should include the final PFS and OPPS rules following CMS’s proposal to retain the current flat-rate methodology for CY27, while any revised DFU/VLU LCDs could further raise the evidence threshold and narrow the reimbursable product set. 

Investment thesis: Buy; TP $1.09 (unchanged) The Myriad growth story remains intact and the outlook for Symphony revenues continues to improve. We make no changes to earnings and maintain our Buy rating and PT of $1.09.

This could make Aroa Biosurgery worth considering if you are looking for exposure to the healthcare sector.

The post Which ASX All Ords share could rocket 90%? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Age Pension is a fortnightly sum paid to Australians aged 67 years or older to help them fund a basic retirement.

The catch is, not everyone over 67 years old is eligible. And the payment amount you could get is heavily dependent on your income and the value of assets you own.

Here’s everything you need to know about the Age Pension income test, the asset test, and how much you could get.

The maximum Age Pension payment

The Age Pension has a maximum total fortnightly payment of $1,200.90 for retired singles and $1,810.40 for couples combined. 

These sums include the maximum basic rate, the maximum pension supplement, and the energy supplement.

How is my final payment level calculated?

Centrelink assesses you under both an income and an asset test. It then applies whichever gives you the lowest rate of payment for your individual circumstances.

What is the Age Pension income test?

The income test assesses all of your income, pooled from all sources.

Your income includes your wages, but also includes anything from superannuation contributions, investment income, bonuses, or commission payments. 

It’s also applicable regardless of your age. 

In order to receive the full Age Pension single Australians can earn up to $226 per fortnight. Meanwhile, couples can earn up to $396 per fortnight.

But the good news is that if you’re over these thresholds, you could still be eligible for some sort of part payment. 

Single Australians can earn up to $2,627.80 per fortnight. Then and couples (living together) can earn up to $4,016.80 per fortnight and still qualify for at least a part-Age Pension, which is assessed on a sliding scale.

For a single person, your Age Pension will reduce by 50 cents for each dollar over $226. For couples it will reduce by 25 cents for each dollar over $396.

It means that the more you earn, the lower your Age Pension payment will be, until it reaches zero.

What about the Age Pension asset test?

The asset test includes everything you own, whether it’s in full, in part, or you have an interest in. It does exclude your primary residence. 

In order to receive the full Age Pension, single homeowners cannot own assets valued at $333,000 or more. For non-homeowners, this will be up to $600,000.

Meanwhile, a couple (combined) can own up to $499,000 in value if they own a property, or $766,000 if they don’t.

Again, as with the income test, if you’re over these thresholds, it’s still possible to get some sort of partial payment.

Single Australians who are homeowners can own assets valued up to $733,500, and single non-homeowners can own assets valued up to $1,000,500, and still be eligible for some level of part-payment.

Couples are also entitled to a partial payment, provided their combined assets don’t exceed $1,102,500 for homeowners. Non-homeowners can own assets totalling no more than $1,369,500.

The post Australian Age Pension: Income test, assets test and payment amounts explained appeared first on The Motley Fool Australia.

More reading

• Here’s what $10,000 invested in ASX tech shares 5 years ago would be worth now
• 4 ASX shares which could improve by 25% to more than 100%
• Which ASX All Ords share could rocket 90%?
• 2 ASX small-caps with 40% upside
• 3 of the best ASX dividend stocks to supplement your superannuation

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.